BioCryst Announces Strong Q3 2024 Revenue Growth
Company Announcements

BioCryst Announces Strong Q3 2024 Revenue Growth

BioCryst ( (BCRX) ) has issued an announcement.

BioCryst Pharmaceuticals reported a strong Q3 2024 with ORLADEYO net revenue of $116.3 million, growing 35.7% year-over-year, and adjusted full-year revenue guidance to $430-$435 million. The company introduced additional revenue guidance of $443-$448 million including RAPIVAB and achieved a GAAP operating profit of $7.7 million. Advancements in their pipeline include BCX17725 for Netherton syndrome and avoralstat for DME, showcasing significant progress and a robust outlook for sustainable profitability.

For detailed information about BCRX stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyBiotech Alert: Searches spiking for these stocks today
TheFlyBioCryst reports inducement grants under Nasdaq listing rule
TheFlyBioCryst price target raised to $8 from $7 at Barclays
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App